E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic prostate cancer |
Metastaattinen eturauhassyöpä |
|
E.1.1.1 | Medical condition in easily understood language |
Metastatic prostate cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
i) Evaluate the lesion-specific expression of prostate-specific membrane antigen (PSMA) and fibroblast activation-protein (FAP) in metastatic prostate cancer |
|
E.2.2 | Secondary objectives of the trial |
ii) Evaluate the potential of fluorine-18 labeled FAP inhibitor (FAPI)-74 positron-emission tomography (PET)/computed tomography (CT) to detect prostate cancer metastases. iii) Evaluate the diagnostic accuracy between fluorine-18 labeled DCFPyL PSMA and FAPI-74 using PET/CT imaging iv) Evaluate the whole tracer-based metastatic load by calculating DCFPyL PSMA and FAPI-74 activated tumor volumes (TV) v) Evaluate the expression of PSMA and FAPI at the tissue level from the original tumor and metastases using immunohistochemistry. vi) Evaluate the effect of clinical characteristics (prostate-specific antigen (PSA) doubling time, type of metastases [bone/node/soft tissue], previous therapy) on the uptake of DCFPyL and FAPI-74 to the individual metastases. vii) Observe vital signs and adverse events (AE) during imaging
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Men with histologically confirmed prostate cancer. Age 50-85 years. WHO performance score 0-2. At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging. All previous treatment lines are allowed. Patient signs informed consent form after receiving written information. |
|
E.4 | Principal exclusion criteria |
Patient is not able to understand the purpose of the study. Medical conditions prohibiting whole-body PET/CT imaging.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
i) The proportion of subject with PSMA- and/or FAPI-positive metastases and number of metastases. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 18F-FAPI-74 PET/CT and 18F- DCFPyL PET/CT imaging. |
|
E.5.2 | Secondary end point(s) |
i) The proportion of detected metastasis with 18F-FAPI-74 PET/CT compared to the 18F- DCFPyL PET/CT. ii) The sensitivity, specificity, accuracy, and area under the receiver-operating characteristic curve (AUC) values of 18F-DCFPyL PET/CT and 18F-FAPI-74 PET/CT in detecting metastatic subjects
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 18F-FAPI-74 PET/CT and 18F- DCFPyL PET/CT imaging. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |